Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
AVALON PHARMACEUTICALS INC (AVRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/02/2009 |
8-K
| Quarterly results |
| 05/06/2009 |
8-K
| Form 8-K -- Current report |
| 04/02/2009 |
8-K
| Form 8-K -- Current report |
| 03/17/2009 |
8-K
| Form 8-K -- Current report |
| 01/14/2009 |
8-K
| Form 8-K -- Current report |
| 12/22/2008 |
8-K
| Form 8-K -- Current report |
| 11/25/2008 |
8-K
| Form 8-K -- Current report |
| 10/30/2008 |
8-K
| Form 8-K -- Current report |
| 10/28/2008 |
8-K
| Other Events, Financial Statements and Exhibits |
| 09/29/2008 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 08/13/2008 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports Second Quarter 2008 Results Company also announces that it is restructuring operations Germantown, Md., August 13, 2008 — Avalon Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics, today announced financial and operational results for the second quarter of 2008. For the three months ended June 30, 2008, net loss was $5.6 million, compared with $5.8 million in the second quarter of 2007. As of June 30, 2008, cash, cash equivalents and marketable securities totaled $16.7 million. The Company also announced today that it is restructuring its operations and reducing its workforce by approximately one-third. “In the second quarter of 2008, we reached an important milestone for Av..." |
|
| 05/07/2008 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports First Quarter 2008 Results Germantown, Md., May 7, 2008 — Avalon Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics, today announced financial and operational results for the first quarter of 2008. For the three months ended March 31, 2008, net loss was $6.2 million, compared with $5.3 million in the first quarter of 2007. As of March 31, 2008, cash, cash equivalents and marketable securities totaled $23.6 million. “Our clinical trials, pre-clinical product development programs and major collaborations continued to progress as planned in the first quarter of 2008,” stated Kenneth C. Carter, Ph.D., President and CEO. “We are excited about recent progress in our Aurora/Centros..." |
|
| 03/19/2008 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results Germantown, MD, March 19, 2008 — Avalon Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics, today announced financial and operational results for the fourth quarter and full year of 2007. For the three months ended December 31, 2007, net loss was $5.1 million, compared with $4.4 million in the fourth quarter of 2006. For the year ended December 31, 2007, net loss was $21.7 million, compared with a loss of $17.1 million for 2006. As of December 31, 2007, cash, cash equivalents and marketable securities totaled $28.5 million. “Avalon continues to execute on our corporate strategy of building a pipeline of first-in-class drugs for Avalo..." |
|
| 03/17/2008 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ... |
| 02/15/2008 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 11/07/2007 |
8-K
| Quarterly results |
| 10/15/2007 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ... |
| 08/08/2007 |
8-K
| Quarterly results |
| 06/07/2007 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 05/29/2007 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 05/10/2007 |
8-K
| Quarterly results |
| 05/04/2007 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ... |
| 04/30/2007 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I... |
| 03/23/2007 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 03/21/2007 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports Fourth Quarter and Full Year 2006 Results Germantown, Md., March 21, 2007 — Avalon Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company using its proprietary technology, AvalonRx®, to discover and develop cancer therapeutics, today announced financial and operational results for the fourth quarter and twelve months ended December 31, 2006. For the three months ended December 31, 2006, total revenues were $0.7 million and net loss was $4.4 million. For the fiscal year ended December 31, 2006, total revenues were $2.7 million and net loss was $17.1 million. As of December 31, 2006, cash, cash equivalents and marketable securities totaled $20.4 million. This amount does not include the $9.5 million of net proceeds from the equity offering completed..." |
|
| 03/08/2007 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 01/24/2007 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits|
Docs:
|
"Avalon Pharmaceuticals Raises $10 Million in Private Placement of Common Stock to Institutional Investors Germantown, Md., Jan. 22, 2007 — Avalon Pharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it had signed definitive agreements on January 19, 2007 with institutional investors for the issuance and sale of 3,000,000 shares of its common stock at $3.34 per share, in a direct private placement to those investors. Gross proceeds of the sale are expected to be $10,020,000. Closing will occur on January 23, 2007, subject to customary closing conditions. The shares offered have not been registered under the federal Securities Act of 1933 or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Avalon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of smal...",
"Avalon Pharmaceuticals Closes $10 Million in Private Placement of Common Stock to Institutional Investors Germantown, Md., Jan. 23, 2007 — Avalon Pharmaceuticals, Inc. , today announced that it has closed the $10 million private placement to institutional investors previously announced on January 22, 2007. A total of 3 million shares of Avalon's common stock were issued in the private placement at a price per share of $3.34. The price represented a $0.26 or 8.4% premium to Avalon's closing price on Friday January 19, 2007. Participants in the transaction included Federated Kaufmann Funds, Merlin Nexus II, L.P., Passport Management, LLC, Xmark Opportunity Funds, Biotechnology Value Fund and other select institutional investors. Proceeds will be used to fund further development of Avalon's lead oncology drug, AVN944, and the continued development of additional pipeline programs using the company's proprietary technology AvalonRx®. “This financing adds to our financial base as we move our..." |
|
| 12/26/2006 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers |
| 12/04/2006 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers |
| 11/07/2006 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports Third Quarter 2006 Results GERMANTOWN, MD, November 7, 2006 — Avalon Pharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced financial and operational results for the third quarter and nine months ended September 30, 2006. “In the third quarter of 2006, our internal discovery and development programs focused on novel drugs to treat cancer continued to make great progress and we continue to be encouraged by the progress of our phase I clinical trial for AVN944, showing tolerance by patients to increasing dose levels,” stated Kenneth C. Carter, Ph.D., President and CEO of Avalon. “Our discovery programs and partnerships with Novartis, MedImmune and ChemDiv also continue to adva..." |
|
| 10/16/2006 |
8-K
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...|
Docs:
|
"Avalon Pharmaceuticals Appoints David Kabakoff, Ph.D., to Its Board of Directors GERMANTOWN, MD, October 13, 2006 — Avalon Pharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of David Kabakoff, Ph.D., to its board of directors effective October 11, 2006. The addition of Dr. Kabakoff brings the Avalon Board to 10 members." |
|
| 09/27/2006 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Principal Officers; Election of Directors; Appointment ...|
Docs:
|
"Offer letter between Avalon Pharmaceuticals, Inc. and David D. Muth",
"Avalon Pharmaceuticals Appoints David D. Muth to Executive Vice President, Chief Business Officer Germantown, MD, September 27, 2006 - Avalon Pharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of David D. Muth to the newly created position of Executive Vice President, Chief Business Officer, effective September 21, 2006. He will report to Kenneth C. Carter, Ph.D., President and CEO of Avalon Pharmaceuticals. “David's appointment marks an important step in the growth of our Company,” said Dr. Carter. “He brings a broad skill set encompassing general management, corporate business development, product development and launch, and strategic planning with an outstanding track record of deli..." |
|
| 08/08/2006 |
8-K
| Quarterly results|
Docs:
|
"Avalon Pharmaceuticals Reports Second Quarter 2006 Results GERMANTOWN, MD, August 8, 2006 — Avalon Pharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced financial and operational results for the second quarter and six months ended June 30, 2006. “As we progress with AVN944 and our drug discovery programs, the recently announced addition of a Chief Medical Officer will help guide clinical development and regulatory strategies,” stated Kenneth C. Carter, Ph.D., President and CEO of Avalon. “We are also very pleased with the progress of our current partnerships and the formation of a new partnership with ChemDiv, Inc. Through these partnerships, which expand the use of our proprietary technology, AvalonRx®,..." |
|
| 08/02/2006 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
|
|
|